Empowering People to be Ambassadors of their Own Health Since 1997.


Monthly Pubmed Review

Monthly Pubmed Review of the Most Relevant Research on Lung Cancer
Literature Review, June 2015



A rare truncating BRCA2 variant and genetic susceptibility to upper aerodigestive tract cancer. Delahaye-Sourdeix M1, Anantharaman D1, Timofeeva MN1, et al. J Natl Cancer Inst. 2015 Apr 2;107(5). pii: djv037. doi: 10.1093/jnci/djv037. Print 2015 May.

Ribonucleotide reductase subunit m2 predicts survival in subgroups of patients with non-small cell lung carcinoma: effects of gender and smoking status. Mah V1, Alavi M1, Márquez-Garbán DC2, et al. PLoS One. 2015 May 22;10(5):e0127600. doi: 10.1371/journal.pone.0127600. eCollection 2015.

Inhibition of 11β-Hydroxysteroid Dehydrogenase Type II Suppresses Lung Carcinogenesis by Blocking Tumor COX-2 Expression as Well as the ERK and mTOR Signaling Pathways. Chang J1, Xue M2, Yang S2, Yao B2, Zhang B3, Chen X3, Pozzi A2, Zhang MZ4. PLoS One. 2015 May 26;10(5):e0127030. doi: 10.1371/journal.pone.0127030. eCollection 2015.

PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Cooper WA1, Tran T2, Vilain RE3, et al. Lung Cancer. 2015 May 18. pii: S0169-5002(15)00243-3. doi: 10.1016/j.lungcan.2015.05.007. [Epub ahead of print]

Genomic copy number signatures uncovered a genetically distinct group from adenocarcinoma and squamous cell carcinoma in non-small cell lung cancer. Lee E1, Moon JW2, Wang X3, et al. Hum Pathol. 2015 May 6. pii: S0046-8177(15)00151-3. doi: 10.1016/j.humpath.2015.04.009. [Epub ahead of print]

Minimally invasive electro-magnetic navigational bronchoscopy-integrated near-infrared-guided sentinel lymph node mapping in the porcine lung. Wada H1, Hirohashi K2, Anayama T2, et al. PLoS One. 2015 May 20;10(5):e0126945. doi: 10.1371/journal.pone.0126945. eCollection 2015.



Projected Clinical, Resource Use, and Fiscal Impacts of Implementing Low-Dose Computed Tomography Lung Cancer Screening in Medicare. Roth JA1, Sullivan SD2, Goulart BH2, Ravelo A2, Sanderson JC2, Ramsey SD2. J Oncol Pract. 2015 May 5. pii: JOP.2014.002600. [Epub ahead of print]

Observer Variability for Classification of Pulmonary Nodules on Low-Dose CT Images and Its Effect on Nodule Management. van Riel SJ1, Sánchez CI, Bankier AA, et al. Radiology. 2015 May 22:142700. [Epub ahead of print]

Poor cell block adequacy rate for molecular testing improved with the addition of Diff-Quik-stained smears: Need for better cell block processing. Harada S1, Agosto-Arroyo E1, Levesque JA1, et al. Cancer Cytopathol. 2015 May 8. doi: 10.1002/cncy.21561. [Epub ahead of print]

The impact of the regimen of screening on lung cancer cure: a comparison of I-ELCAP and NLST. Yip R, Henschke CI, Yankelevitz DF, Boffetta P, Smith JP; International Early Lung Cancer

The association between combined non-cystic fibrosis bronchiectasis and lung cancer in patients with chronic obstructive lung disease. Kim YW1, Jin KN2, Heo EY3, Park SS3, Chung HS3, Kim DK3. Int J Chron Obstruct Pulmon Dis. 2015 May 4;10:873-9. doi: 10.2147/COPD.S80439. eCollection 2015.

Progress in the development of volatile exhaled breath signatures of lung cancer. Mazzone PJ1, Wang XF, Lim S, et al. Ann Am Thorac Soc. 2015 May;12(5):752-7. doi: 10.1513/AnnalsATS.201411-540OC.

Derivation of a bronchial genomic classifier for lung cancer in a prospective study of patients undergoing diagnostic bronchoscopy. Whitney DH1,2, Elashoff MR3, Porta-Smith K4,5, et al. BMC Med Genomics. 2015 May 6;8(1):18. doi: 10.1186/s12920-015-0091-3.

Circulating MicroRNAs as Non-Invasive Biomarkers for Early Detection of Non-Small-Cell Lung Cancer. Wozniak MB1, Scelo G1, Muller DC1, Mukeria A2, Zaridze D2, Brennan P1. PLoS One. 2015 May 12;10(5):e0125026. doi: 10.1371/journal.pone.0125026. eCollection 2015.

Association of TERT Polymorphisms with Clinical Outcome of Non-Small Cell Lung Cancer Patients. Zhao X1, Wang S2, Wu J3, et al. PLoS One. 2015 May 28;10(5):e0129232. doi: 10.1371/journal.pone.0129232. eCollection 2015.


Long-term outcomes of open and video-assisted thoracoscopic lung lobectomy for the treatment of early stage non-small cell lung cancer are similar: a propensity-matched study. Murakawa T1, Ichinose J, Hino H, Kitano K, Konoeda C, Nakajima J. World J Surg. 2015 May;39(5):1084-91. doi:

Patterns of Recurrence and Survival after Surgery or Stereotactic Radiotherapy for Early Stage NSCLC. van den Berg LL1, Klinkenberg TJ, Groen HJ, Widder J. J Thorac Oncol. 2015 May;10(5):826-31. doi: 10.1097/JTO.0000000000000483.

Surgical Outcomes of Lung Cancer in Patients with Combined Pulmonary Fibrosis and Emphysema. Mimae T1, Suzuki K, Tsuboi M, et al. Ann Surg Oncol. 2015 May 9. [Epub ahead of print]

Racial and Ethnic Differences in Lung Cancer Surgical Stage: An STS Database Study. Weksler B1, Kosinski AS2, Burfeind WR3, Silvestry SC4, Sullivan J1, D’Amico TA5. Thorac Cardiovasc Surg. 2015 May 18. [Epub ahead of print]

Impact of Pulmonary Function Measurements on Long-Term Survival After Lobectomy for Stage I Non-Small Cell Lung Cancer. Berry MF1, Jeffrey Yang CF2, et al. Ann Thorac Surg. 2015 May 16. pii: S0003-4975(15)00291-X. doi: 10.1016/j.athoracsur.2015.02.076. [Epub ahead of print]

Image-guided video assisted thoracoscopic surgery (iVATS) – phase I-II clinical trial. Gill RR1, Zheng Y2, Barlow JS2, et al. J Surg Oncol. 2015 May 28. doi: 10.1002/jso.23941. [Epub ahead of print]

Bilobectomy Versus Lobectomy for Non-Small Cell Lung Cancer: A Comparative Study of Outcomes, Long-Term Survival, and Quality of Life. Xie D1, Deschamps C2, Shen RK2, et al. Ann Thorac Surg. 2015 May 22. pii: S0003-4975(15)00399-9. doi: 10.1016/j.athoracsur.2015.03.018. [Epub ahead of print]



Proteomic Profiling of Paclitaxel Treated Cells Identifies a Novel Mechanism of Drug Resistance Mediated by PDCD4. Xu H1, Dephoure N2, Sun H1, et al. J Proteome Res. 2015 May 14. [Epub ahead of print]

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. Brahmer J1, Reckamp KL, Baas P, et al. N Engl J Med. 2015 May 31. [Epub ahead of print]

miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy. Wang F1, Lou JF1, Cao Y1, et al. Exp Mol Med. 2015 May 8;47:e162. doi: 10.1038/emm.2015.17.

Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations. Inoue Y1, Inui N, Asada K, et al. Cancer Chemother Pharmacol. 2015 May 24. [Epub ahead of print]

Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations. Yokoyama Y1, Sonobe M, Yamada T, et al. Int J Clin Oncol. 2015 May 8. [Epub ahead of print]

NOB1 expression predicts early response to Cisplatin-based chemotherapy in patients with advanced non-small cell lung cancer. Liu K, Chen HL, Gu MM, You QS. J Chemother. 2015 May 13:1973947815Y0000000041. [Epub ahead of print]

Use of Adjuvant Cisplatin-Based Versus Carboplatin-Based Chemotherapy in Non-Small-Cell Lung Cancer: Findings From the Florida Initiative for Quality Cancer Care. Tanvetyanon T1, Lee JH2, Fulp WJ2, et al. J Oncol Pract. 2015 May 19. pii: JOP.2014.001750. [Epub ahead of print]

Second-line docetaxel for patients with platinum-refractory advanced non-small cell lung cancer and interstitial pneumonia. Watanabe N1, Niho S, Kirita K, et al. Cancer Chemother Pharmacol. 2015 May 15. [Epub ahead of print]

Oral vinorelbine plus cisplatin followed by maintenance oral vinorelbine as first-line treatment for advanced non-small cell lung cancer. Farhat FS1, Ghosn MG, Kattan JG. Cancer Chemother Pharmacol. 2015 May 30. [Epub ahead of print]

BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. Zhou C1, Wu YL2, Chen G2, et al. J Clin Oncol. 2015 May 26. pii: JCO.2014.59.4424. [Epub ahead of print]


Salvage stereotactic body radiotherapy for locally recurrent non-small cell lung cancer after sublobar resection and i(125) vicryl mesh brachytherapy. Gill BS1, Clump DA1, Burton SA1, Christie NA2, Schuchert MJ2, Heron DE1. Front Oncol. 2015 May 11;5:109. doi: 10.3389/fonc.2015.00109. eCollection 2015.

A comparison of two clinical correlation models used for real-time tumor tracking of semi-periodic motion: A focus on geometrical accuracy in lung and liver cancer patients. Poels K1, Dhont J2, Verellen D3, et al. Radiother Oncol. 2015 May 14. pii: S0167-8140(15)00213-3. doi: 10.1016/j.radonc.2015.05.004. [Epub ahead of print]

Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer. Nguyen QN1, Ly NB2, Komaki R2, et al. Radiother Oncol. 2015 May 28. pii: S0167-8140(15)00249-2. doi: 10.1016/j.radonc.2015.05.014. [Epub ahead of print]

Cancer-associated fibroblasts from lung tumors maintain their immunosuppressive abilities after high-dose irradiation. Gorchs L1, Hellevik T2, Bruun JA3, et al. Front Oncol. 2015 May 12;5:87. doi: 10.3389/fonc.2015.00087. eCollection 2015.

Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. Bezjak A1, Temin S1, Franklin G1, et al. J Clin Oncol. 2015 May 5. pii: JCO.2014.59.2360. [Epub ahead of print]

Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors.Chaudhuri AA1, Tang C1, Binkley MS1, et al. Lung Cancer. 2015 May 4. pii: S0169-5002(15)00232-9. doi: 10.1016/j.lungcan.2015.04.014. [Epub ahead of print]

Motion mitigation for lung cancer patients treated with active scanning proton therapy. Grassberger C1, Dowdell S2, Sharp G2, Paganetti H2. Med Phys. 2015 May;42(5):2462. doi: 10.1118/1.4916662.

Bayesian network ensemble as a multivariate strategy to predict radiation pneumonitis risk.Lee S1, Ybarra N1, Jeyaseelan K1, et al. Med Phys. 2015 May;42(5):2421. doi: 10.1118/1.4915284.

Adjuvant radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline. Rodrigues G1, Choy H2, Bradley J3, et al. Pract Radiat Oncol. 2015 May-Jun;5(3):149-55. doi: 10.1016/j.prro.2015.02.013.



90Y-Labeled Anti-ROBO1 Monoclonal Antibody Exhibits Antitumor Activity against Small Cell Lung Cancer Xenografts. Fujiwara K1, Koyama K1, Suga K2, et al. PLoS One. 2015 May 27;10(5):e0125468. doi: 10.1371/journal.pone.0125468. eCollection 2015.

Tumor Spread through Air Spaces is an Important Pattern of Invasion and Impacts the Frequency and Location of Recurrences after Limited Resection for Small Stage I Lung Adenocarcinomas. Kadota K1, Nitadori J, Sima CS, Ujiie H, Rizk NP, Jones DR, Adusumilli PS, Travis WD. J Thorac Oncol. 2015 May;10(5):806-14. doi: 10.1097/JTO.0000000000000486.

Brain damage following prophylactic cranial irradiation in lung cancer survivors. Simó M1, Vaquero L, Ripollés P, et al. Brain Imaging Behav. 2015 May 27. [Epub ahead of print]

Small cell lung cancer: will recent progress lead to improved outcomes? Pietanza MC1, Byers LA2, Minna JD3, Rudin CM4. Clin Cancer Res. 2015 May 15;21(10):2244-55. doi: 10.1158/1078-0432.CCR-14-2958.

Early Prediction of Disease Progression in Small Cell Lung Cancer: Toward Model-Based Personalized Medicine in Oncology. Buil-Bruna N1, Sahota T2, López-Picazo JM3, et al. Cancer Res. 2015 May 4. [Epub ahead of print]

Initiation and characterization of small cell lung cancer patient-derived xenografts from ultrasound-guided transbronchial needle aspirates. Anderson WC1, Boyd MB2, Aguilar J1, et al. PLoS One. 2015 May 8;10(5):e0125255. doi: 10.1371/journal.pone.0125255. eCollection 2015.

Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702. Inoue A1, Sugawara S2, Maemondo M3, et al. Lung Cancer. 2015 May 4. pii: S0169-5002(15)00211-1. doi: 10.1016/j.lungcan.2015.04.012. [Epub ahead of print]

Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer. Ding X1, Cao H2, Chen X3, et al. J Transl Med. 2015 May 13;13:158. doi: 10.1186/s12967-015-0514-0.

Elevated RABEX-5 protein expression predicts poor prognosis in combined small cell lung cancer. Zhang F1, Zhang M, Hu G, Cai Q, Xu T. Tumour Biol. 2015 May 23. [Epub ahead of print]

Metformin use improves the survival of diabetic combined small-cell lung cancer patients. Kong F1, Gao F, Liu H, et al. Tumour Biol. 2015 May 16. [Epub ahead of print]


Pulmonologist involvement, stage-specific treatment, and survival in adults with non-small cell lung cancer and chronic obstructive pulmonary disease. Deepak JA1, Ng X, Feliciano J, Mao L, Davidoff AJ. Ann Am Thorac Soc. 2015 May;12(5):742-51. doi: 10.1513/AnnalsATS.201406-230OC.

Treatment complexity: a description of chemotherapy and supportive care treatment visits in patients with advanced-stage cancer diagnoses. Sumpio C1, Knobf MT, Jeon S. Support Care Cancer. 2015 May 31. [Epub ahead of print]

Pulmonary Rehabilitation in Advanced Lung Cancer Patients During Chemotherapy. Jastrzębski D1, Maksymiak M, Kostorz S, et al. Adv Exp Med Biol. 2015 May 28. [Epub ahead of print]

A Pilot Study of a Mobile Health Pain Coping Skills Training Protocol for Patients with Persistent Cancer Pain. Somers TJ1, Abernethy AP1, Edmond SN1, Kelleher SA2, Wren AA1, Samsa GP1, Keefe FJ1. J Pain Symptom Manage. 2015 May 26. pii: S0885-3924(15)00235-3. doi: 10.1016/j.jpainsymman.2015.04.013. [Epub ahead of print]



Nuciferine, extracted from Nelumbo nucifera Gaertn, inhibits tumor-promoting effect of nicotine involving Wnt/β-catenin signaling in non-small cell lung cancer. Liu W1, Yi DD2, Guo JL3, Xiang ZX3, Deng LF4, He L5. J Ethnopharmacol. 2015 May 13;165:83-93. doi: 10.1016/j.jep.2015.02.015. Epub 2015 Feb 16.

The novel herbal cocktail MA128 suppresses tumor growth and the metastatic potential of highly malignant tumor cells. Kim A1, Im M1, Yim NH1, Hwang YH1, Yang HJ1, Ma JY1. Oncol Rep. 2015 May 29. doi: 10.3892/or.2015.4018. [Epub ahead of print]


Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. Sholl LM1, Aisner DL, Varella-Garcia M, et al. J Thorac Oncol. 2015 May;10(5):768-77. doi: 10.1097/JTO.0000000000000516.

Motivation and preferences of exercise programmes in patients with inoperable metastatic lung cancer: a need assessment. Kartolo A1, Cheng S, Petrella T. Support Care Cancer. 2015 May 9. [Epub ahead of print]

Residential radon and lung cancer characteristics in never smokers. Torres-Durán M, Ruano-Ravina A, Parente-Lamelas I, et al. Int J Radiat Biol. 2015 May 13:1-24. [Epub ahead of print]

Incidence trends of lung cancer by immigration status among Chinese Americans. Gomez SL1, Yang J2, Lin SW3, et al. Cancer Epidemiol Biomarkers Prev. 2015 May 19. pii: cebp.0123.2015. [Epub ahead of print]

Common Oncogene Mutations and Novel SND1-BRAF Transcript Fusion in Lung Adenocarcinoma from Never Smokers. Jang JS1, Lee A2, Li J3, et al. Sci Rep. 2015 May 18;5:9755. doi: 10.1038/srep09755.

Vaccine immunotherapy in lung cancer: Clinical experience and future directions. Freeman-Keller M1, Goldman J1, Gray J2. Pharmacol Ther. 2015 May 16. pii: S0163-7258(15)00095-9. doi: 10.1016/j.pharmthera.2015.05.004. [Epub ahead of print]

Patients and Physicians Can Discuss Costs of Cancer Treatment in the Clinic. Kelly RJ1, Forde PM1, Elnahal SM1,et al. J Oncol Pract. 2015 May 26. pii: JOP.2015.003780. [Epub ahead of print]

Time to treatment as a quality metric in lung cancer: Staging studies, time to treatment, and patient survival. Gomez DR1, Liao KP2, Swisher SG3, et al. Radiother Oncol. 2015 May 23. pii: S0167-8140(15)00197-8. doi: 10.1016/j.radonc.2015.04.010. [Epub ahead of print]

Caring Ambassadors Program, Inc. | P.O. Box 1748 | Oregon City, OR 97045 | 503-632-9032 | 503-632-9038 (Fax)